Quick Answer
GYRE THERAPEUTICS, INC. reported Cash and Equivalents of $37.07 million for fiscal year 2025.
GYRE THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $37.07M | +213.8% |
| 2024 | $11.81M | -64.7% |
| 2023 | $33.51M | +33.1% |
| 2022 | $25.18M | -43.2% |
| 2021 | $44.35M | +46.1% |
| 2020 | $30.36M | +97.5% |
| 2019 | $15.37M | -50.8% |
| 2018 | $31.21M | +115.7% |
| 2017 | $14.47M | +41.0% |
| 2016 | $10.26M | -64.7% |
| 2015 | $29.10M | +1784.5% |
| 2014 | $1.54M | -45.4% |
| 2013 | $2.83M | -16.8% |
| 2012 | $3.40M | -96.8% |
| 2011 | $107.28M | -35.3% |
| 2010 | $165.85M | +97.7% |
| 2009 | $83.91M | +63.9% |
| 2008 | $51.20M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.40M | +154.6% | +10.7% |
| June 30, 2025 | $36.49M | +126.7% | +142.5% |
| March 31, 2025 | $15.04M | -49.5% | +27.4% |
| December 31, 2024 | $11.81M | -64.7% | -25.5% |
| September 30, 2024 | $15.87M | +612.1% | -1.4% |
| June 30, 2024 | $16.10M | +132.5% | -46.0% |
| March 31, 2024 | $29.79M | +267.8% | -11.1% |
| December 31, 2023 | $33.51M | +54.7% | +1404.0% |
- GYRE THERAPEUTICS, INC. showed an increase of +213.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, GYRE THERAPEUTICS, INC.’s cash and equivalents has declined by 27.6% (from $51.20 million to $37.07 million).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: